53039-49-9

Basic information

• Product Name: Benzene, 1-bromo-3-[(4-methoxyphenyl)methyl]-
• CAS NO: 53039-49-9
• Molecular Formula: C14H13BrO
• Molecular Weight: 277.161
• Mol File: 53039-49-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzene, 1-bromo-3-[(4-methoxyphenyl)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-bromo-3-[(4-methoxyphenyl)methyl]-(53039-49-9)
• EPA Substance Registry System: Benzene, 1-bromo-3-[(4-methoxyphenyl)methyl]-(53039-49-9)

Safety Data

• Hazardous Substances Data: 53039-49-9(Hazardous Substances Data)

Upstream product

• 138112-75-1 (3-bromophenyl)(4-methoxyphenyl)methanol 
• 13139-86-1 4-methoxyphenyl magnesium bromide 
• 100-66-3 methoxybenzene 
• 54118-76-2 (3-bromophenyl)(4-methoxyphenyl)methanone 
• 585-76-2 m-bromobenzoic acid 
• 823-78-9 meta-bromobenzyl bromide 
• 33397-21-6 tris(4-methoxyphenyl)bismuth 

Relevant articles and documents

Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia

Therapeutic angiogenesis is a potential therapeutic strategy for hind limb ischemia (HLI); however, currently, there are no small-molecule drugs capable of inducing it at the clinical level. Activating the hypoxia-inducible factor-1 (HIF-1) pathway in skeletal muscle induces the secretion of angiogenic factors and thus is an attractive therapeutic angiogenesis strategy. Using salidroside, a natural glycosidic compound as a lead, we performed a structure-activity relationship (SAR) study for developing a more effective and druggable angiogenesis agent. We found a novel glycoside scaffold compound (C-30) with better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells. This in turn significantly increased the angiogenic potential of vascular endothelial and smooth muscle cells and, subsequently, induced the formation of mature, functional blood vessels in diabetic and nondiabetic HLI mice. Together, this study offers a novel, promising small-molecule-based therapeutic strategy for treating HLI.

C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

C-Aryl 5a-carba-β-d-glucopyranose derivatives were synthesized and evaluated for inhibition activity against hSGLT1 and hSGLT2. Modifications to the substituents on the two benzene rings resulted in enhanced hSGLT2 inhibition activity and extremely high h